open access
Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: A three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessments
open access
Abstract
Methods: Four women exhibiting sinus rhythm with a resting HR ≥ 100 bpm and an average HR ≥ 90 bpm (Holter monitoring) were followed for three months. Structural heart disease and other causes of tachycardia were discarded. Electrocardiographic, Holter monitoring, exercise tolerance and quality of life determinations were performed. Ivabradine was initiated at 5 mg (bid) and increased to 7.5 mg (bid) after one week.
Results: All patients (mean age 33.7 years) presented a typical history of effort intolerance, palpitations and tachycardia. Resting HR (bpm) was decreased: 106.5 ± 3 to 88.5 ± 2 (week 1), to 77.0 ± 3 (week 2) and to 73.7 ± 13 (month 3). Reductions (Holter monitoring) of the maximum, average and minimum HR (beats) were: 152.0 ± 19 to 128.5 ± 18; 96.0 ± 1.4 to 73 ± 3.2 and 63.2 ± 6 to 48.2 ± 3. Total exercise time was amplified (555 ± 99 to 679 ± 90 s) and quality of life improved.
Conclusions: IST causes an elevated HR and its control is the treatment objective. If future data confirm our results, ivabradine could be used for this purpose. More information is necessary in order to define its role: initial option, second step (β-blockers non-responders or intolerants) or combined (refractory cases).
(Cardiol J 2010; 17, 2: 166-171)
Abstract
Methods: Four women exhibiting sinus rhythm with a resting HR ≥ 100 bpm and an average HR ≥ 90 bpm (Holter monitoring) were followed for three months. Structural heart disease and other causes of tachycardia were discarded. Electrocardiographic, Holter monitoring, exercise tolerance and quality of life determinations were performed. Ivabradine was initiated at 5 mg (bid) and increased to 7.5 mg (bid) after one week.
Results: All patients (mean age 33.7 years) presented a typical history of effort intolerance, palpitations and tachycardia. Resting HR (bpm) was decreased: 106.5 ± 3 to 88.5 ± 2 (week 1), to 77.0 ± 3 (week 2) and to 73.7 ± 13 (month 3). Reductions (Holter monitoring) of the maximum, average and minimum HR (beats) were: 152.0 ± 19 to 128.5 ± 18; 96.0 ± 1.4 to 73 ± 3.2 and 63.2 ± 6 to 48.2 ± 3. Total exercise time was amplified (555 ± 99 to 679 ± 90 s) and quality of life improved.
Conclusions: IST causes an elevated HR and its control is the treatment objective. If future data confirm our results, ivabradine could be used for this purpose. More information is necessary in order to define its role: initial option, second step (β-blockers non-responders or intolerants) or combined (refractory cases).
(Cardiol J 2010; 17, 2: 166-171)
Keywords
inappropriate sinus tachycardia; ivabradine


Title
Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: A three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessments
Journal
Issue
Pages
166-171
Published online
2010-03-29
Page views
847
Article views/downloads
1979
Bibliographic record
Cardiol J 2010;17(2):166-171.
Keywords
inappropriate sinus tachycardia
ivabradine
Authors
Edgardo Kaplinsky
Francesc Planas Comes
Ludmila San Vicente Urondo
Francesc Planas Ayma